NCT02245412 - A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 14, 2014

Primary Completion Date

February 27, 2017

Study Completion Date

February 27, 2017

Conditions

Acute Graft-Versus-Host DiseaseGIGVHD

Interventions

BIOLOGICAL

ALXN1007 10 mg/kg once weekly

ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.

BIOLOGICAL

ALXN1007 20 mg/kg once weekly

ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.

BIOLOGICAL

ALXN1007 20 mg/kg twice weekly

ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.

Trial Locations (12)

Roswell Park Cancer Institute, Buffalo

Abramson Cancer Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia

Emory University Hospital, Atlanta

Groupe Hospitalier Sud - Hôpital Haut-Lévêque - Centre François, Gironde

CHU de Grenoble - Hôpital Nord, Grenoble

Barbara Ann Karmanos Cancer Institute, Detroit

University of Minnesota Medicine - Hematology, Oncology and Transplantation Office, Minneapolis

Washington University in St. Louis, St Louis

Hôpital Saint-Louis, Paris

The University of Texas MD Anderson Cancer Center, Houston

City of Hope, Duarte

Hackensack University Medical Center, Hackensack